Loading clinical trials...
Loading clinical trials...
A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Of The Safety, Clinical Activity And Pharmacokinetics Of Bosutinib (PF-05208763) Versus Placebo In Subjects With Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Conditions
Interventions
Bosutinib
Bosutinib
+1 more
Locations
67
United States
Southwest Kidney Institute, PLC
Phoenix, Arizona, United States
Southwest Clinical Research Institute, LLC
Tempe, Arizona, United States
Southwest Kidney Institute, PLC
Tempe, Arizona, United States
Capital Nephrology Clinical Research
Sacramento, California, United States
Boise Kidney & Hypertension Institute, PLLC
Caldwell, Idaho, United States
Boise Kidney & Hypertension Institute, PLLC
Meridian, Idaho, United States
Start Date
December 1, 2010
Primary Completion Date
July 1, 2014
Completion Date
August 1, 2014
Last Updated
March 11, 2016
NCT04534985
NCT01559363
NCT03342742
NCT02903511
NCT04310319
NCT00410007
Lead Sponsor
Pfizer
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions